In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Novavax, with a price target of $207.00. The company’s shares closed last Tuesday at $83.80, close to its 52-week low of $65.82.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 27.9% and a 37.2% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Citius Pharmaceuticals.
Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $179.86, representing a 130.4% upside. In a report issued on March 14, Jefferies also assigned a Buy rating to the stock with a $198.00 price target.